Eric Harold Yecies
Known title: CCO and General CounselCIK: 0001834563
Eric Harold Yecies's purchase track record
How the stock did after each of Eric Harold Yecies's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since November 23, 2021
Stock higher 6 months later
33%
3 months: 33%
Median 6-month return
-13.3%
3 months: -14.6%
Beat the S&P 500
33%
median -11.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/13/2023 | LFMD | $30K | +62.8% | +179.3% | +6.3% |
| 3/14/2022 | LFMD | $16K | -29.1% | -13.3% | -1.5% |
| 11/23/2021 | LFMD | $30K | -14.6% | -48.0% | -16.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LFMD | ▲ Buy | Grant | 50,000 | $0 | 8/22/2025 | View on chart |
| LFMD | ▼ Sell | Open Market | 15,000 | $184K | 6/13/2025 | View on chart |
| LFMD | ▲ Buy | Grant | 18,750 | $0 | 3/31/2025 | View on chart |
| LFMD | ▲ Buy | Grant | 30,000 | $0 | 3/31/2025 | View on chart |
| LFMD | ▲ Buy | Grant | 50,000 | $0 | 3/7/2025 | View on chart |
| LFMD | ▲ Buy | Grant | 56,250 | $0 | 3/21/2024 | View on chart |
| LFMD | ▲ Buy | Grant | 150,000 | — | 6/15/2023 | View on chart |
| LFMD | ▲ Buy | Open Market | 11,500 | $30K | 6/13/2023 | View on chart |
| LFMD | ▲ Buy | Open Market | 5,000 | $16K | 3/14/2022 | View on chart |
| LFMD | ▲ Buy | Option Exercise | 12,500 | $0 | 1/27/2022 | View on chart |
| LFMD | ▲ Buy | Open Market | 7,400 | $30K | 11/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
LifeMD Announces Preferred Dividend and AT&T Partnership
LifeMD declared a quarterly dividend on its Series A cumulative perpetual preferred stock. The company also announced a partnership with AT&T that will provide free memberships, with the potential to convert some users into paying patients. These developments come as the common stock trades near its recent support level and the firm carries a high trailing P/E.
LifeMD Announces Preferred Dividend and AT&T Partnership. LifeMD declared a quarterly dividend on its Series A cumulative perpetual preferred stock. The company also announced a partnership with AT&T that will provide free memberships, with the potential to convert some users into paying patients. These developments come as the common stock trades near its recent support level and the firm carries a high trailing P/E.